Symptomatic therapy in multiple sclerosis: The role of cannabinoids in treating spasticity

Therapeutic Advances in Neurological Disorders

Volumn 5, Issue 5, 2012, Pages 255-266

  Leussink, Verena Isabell ^a   Husseini, Leila ^a   Warnke, Clemens ^a   Hartung, Hans Peter ^a   Broussalis, Erasmia ^b   Kieseier, Bernd C ^c  

^a Department of Orthopedic Surgery   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

cannabidiol; multiple sclerosis; nabiximols; spasticity; 9 tetrahydrocannabinol

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; BACLOFEN; BOTULINUM TOXIN; CANNABIS; DRONABINOL; NABILONE; NABIXIMOLS; PLACEBO; RIMONABANT;

ALLERGY; ANOREXIA; ASTHENIA; BALANCE IMPAIRMENT; BLURRED VISION; CENTRAL NERVOUS SYSTEM; COMPARATIVE STUDY; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISORIENTATION; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; DYSPHORIA; EUPHORIA; EXCITOTOXICITY; FATIGUE; HALLUCINATION; HUMAN; INCREASED APPETITE; INTOXICATION; MAXIMUM PLASMA CONCENTRATION; MEMORY DISORDER; MOUTH ULCER; MULTIPLE SCLEROSIS; MUSCLE STRENGTH; NAUSEA; NEGATIVE FEEDBACK; NERVOUS SYSTEM; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARANOIA; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SCORING SYSTEM; SEDATION; SEIZURE; SIDE EFFECT; SMOKING; SPASTICITY; SUICIDAL IDEATION; TACHYCARDIA; VISUAL ANALOG SCALE; WEAKNESS; XEROSTOMIA;

EID: 84868245558     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285612453972     Document Type: Review

References (37)

1. Aldington S. Harwood M. Cox B. Weatherall M. Beckert L. Hansell A. et al. Cannabis and Respiratory Disease Research Group (2008) Cannabis use and risk of lung cancer: a case–control study. Eur Respir J 31: 280–286.
2. Basu S. Dittel B. (2011) Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol Res 51: 26–38.
3. Brainin M. Barnes M. Baron J. Gilhus N. Hughes R. Selmaj K. et al. Guideline Standards Subcommittee of the EFNS Scientific Committee (2004) Guidance for the preparation of neurological management guidelines by EFNS scientific task forces – revised recommendations 2004. Eur J Neurol 11: 577–581.
4. Cabral G. Raborn E. Griffin L. Dennis J. Marciano-Cabral F. (2008) CB 2 receptors in the brain: role in central immune function. Br J Pharmacol 153: 240–251.
5. Collin C. Davies P. Mutiboko I. Ratcliffe S. (2007) Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur J Neurol 14: 290–296.
6. Console-Bram L. Marcu J. Abood M. (2012) Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry 28 Feb (epub ahead of print).
7. Correia de Sa J. Airas L. Bartholome E. et al. (2011) Symptomatic therapy in multiple sclerosis – a review for a multimodal approach in clinical practice. Therap Adv Neurol Disord 4: 139–168.
8. Fernandez-Ruiz J. Hernandez M. Ramos J. (2010) Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16: e72–e91.
9. Fleuren J. Voerman G. Erren-Wolters C. Snoek G. Rietman J. Hermens H. et al. (2010) Stop using the Ashworth Scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 81: 46–52.
10. Gowran A. Noonan J. Campbell V. (2011) The multiplicity of action of cannabinoids: implications for treating neurodegeneration. CNS Neurosci Ther 17: 637–644.
11. Jamontt J. Molleman A. Pertwee R. Parsons M. (2010) The effects of Delta-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis. Br J Pharmacol 160: 712–723.
12. Jean-Gilles L. Feng S. Tench et al. (2009) Plasma endocannabinoid levels in multiple sclerosis. J Neurol Sci 287: 212–215.
13. Karst M. Wippermann S. Ahrens J. (2010) Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs 70: 2409–2438.
14. Killestein J. Hoogervorst E. Reif M. Kalkers N. van Loenen A. Staats P. et al. (2002) Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology 58: 1404–1407.
15. Kubajewska I. Constantinescu C. (2010) Cannabinoids and experimental models of multiple sclerosis. Immunobiology 215: 647–657.
16. Notcutt W. Langford R. Davies P. Ratcliffe S. Potts R. (2012) A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler 18: 219–228.
17. Novotna A. Mares J. Ratcliffe S. et al. (2011) A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex((R)) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur J Neurol 18: 1122–1131.
18. Papathanasopoulos P. Messinis L. Lyros E. Kastellakis A. Panagis G. (2008) Multiple sclerosis, cannabinoids, and cognition. J Neuropsychiat Clin Neurosci 20: 36–51.
19. Petrosino S. Di Marzo V. (2010) FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs 11: 51–62.
20. Pryce G. Baker D. (2007) Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors. Br J Pharmacol 150: 519–525.
21. Rieder S. Chauhan A. Singh U. Nagarkatti M. Nagarkatti P. (2010) Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology 215: 598–605.
22. Robson P. (2011) Abuse potential and psychoactive effects of delta-9-tetrahydrocannabinol and cannabidiol oromucosal spray (Sativex), a new cannabinoid medicine. Expert Opin Drug Saf 10: 675–685.
23. Rog D. (2010) Cannabis-based medicines in multiple sclerosis – a review of clinical studies. Immunobiology 215: 658–672.
24. Russo E. Guy G. (2006) A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66: 234–246.
25. Samkoff L. Goodman A. (2011) Symptomatic management in multiple sclerosis. Neurol Clin 29: 449–463.
26. Sánchez A. García-Merino A. (2010) Neuroprotective agents: cannabinoids. Clin Immunol 142: 57–67.
27. Smith P. (2007) Symptomatic treatment of multiple sclerosis using cannabinoids: recent advances. Expert Rev Neurother 7: 1157–1163.
28. Snow B.J. Tsui J.K. Bhatt M.H. Varelas M. Hashimoto S.A. Calne D.B. (1990) Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol 28: 512–515.
29. Sunnerhagen K. (2010) Stop using the Ashworth scale for the assessment of spasticity. J Neurol Neurosurg Psychiatry 81: 2.
30. United Kingdom Tizanidine Trial Group (1994) A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 44: S70–S78.
31. Vaney C. Heinzel-Gutenbrunner M. Jobin P. Tschopp F. Gattlen B. Hagen U. et al. (2004) Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. Mult Scler 10: 417–424.
32. Wade D. Collin C. Stott C. Duncombe P. (2010) Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 16: 707–714.
33. Wade D. Makela P. House H. Bateman C. Robson P. (2006) Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler 12: 639–645.
34. Wang T. Collet J. Shapiro S. Ware M. (2008) Adverse effects of medical cannabinoids: a systematic review. CMAJ 178: 1669–1678.
35. Wegener N. Koch M. (2009) Neurobiology and systems physiology of the endocannabinoid system. Pharmacopsychiatry 42(Suppl. 1): S79–S86.
36. Zajicek J. Fox P. Sanders H. Wright D. Vickery J. Nunn A. et al ; UK MS Research Group (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517–1526.
37. Zajicek J.P. Sanders H.P. Wright D.E. Vickery P.J. Ingram W.M. Reilly S.M. et al. (2005) Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 76: 1664–1669.